Ottawa should reset its relationship with drug developers to improve patient health: Rawson and Adams for Inside Policy
By Nigel Rawson and John Adams, May 2, 2022 On April 14, 2022, Health Minister Jean-Yves Duclos announced the federal ...
Tag: Nigel Rawson
‘Big Tobacco’ COVID-19 vaccine: What were the Liberals thinking? Nigel Rawson and John Adams for the Financial Post
This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, April 22, 2022 After being late to ...
The Macdonald-Laurier Institute Welcomes Newest Senior Fellows, Nigel Rawson and John Adams
OTTAWA, ON (April 11, 2022): We are pleased to announce that Nigel Rawson and John Adams will be joining the ...
Timely access for patients to innovative medicines – A policy change overdue: Rawson and Adams for Inside Policy
By Nigel Rawson and John Adams, March 24, 2022 Much has been written over the last few years about the ...
Time to decide: Do we want foreign R&D or not? Richard C. Owens and Nigel Rawson in the Financial Post
This article originally appeared in the Financial Post. Below is an excerpt from the article, which can be read in ...
National drug plan process doesn’t add up: Nigel Rawson in the Hamilton Spectator
This article originally appeared in the Hamilton Spectator. By Nigel Rawson, February 23, 2022 Theatre of the Absurd features plays ...
Canadians will pay a heavy price as Ottawa cuts drug costs
A new MLI commentary warns that pending and aggressive drug price control efforts could lead to major unintended consequences in ...
Patients’ access to innovative medicines should be an election issue: Rawson and Vanstone in the Hamilton Spectator
Canadians have heard little from any political party in the election campaign about how they will improve access to innovative medicines ...
False Premise – Federal Regulation of Drug Prices as a Step to National Pharmacare: Rawson and Adams in the National Newswatch
Advocates for national pharmacare who insist on control of drug prices, not by negotiation but by federal regulation, may have ...
Appeal court exposes PMPRB abuse of power and bias on drug pricing: Nigel Rawson and John Adams in the Financial Post
The Appeal Court’s unanimous decision demonstrates that the Patented Medicine Prices Review Board is out of control in an anti-industry, ...
Time for the PMPRB to go: Nigel Rawson and Brett Skinner in the Hill Times
The PMPRB has abused its independence. The functional purpose of the PMPRB is no longer relevant, write Nigel Rawson and ...
New Federal Regulations to Reduce Drug Prices Will Only Hinder Innovation: New MLI Paper by Nigel Rawson and John Adams
OTTAWA, ON (June 3, 2021): The COVID-19 pandemic has unmasked a dangerous lack of investment in pharmaceutical and vaccine research, development, and ...
Top News
-
Holding the government accountable for using the Emergencies Act: Ryan Alford for Inside Policy
-
The frontline voices: Tigrayans speak on the realities of life under an insurgency regime
-
Sovereignty in the Arctic and the struggles of the CC-295 Kingfisher: Richard Shimooka in the Hill Times
-
How should NATO respond to Russia’s challenge to European security and stability? New MLI report
-
Canadian Surface Combatant program remains best option for Royal Canadian Navy: Richard Shimooka in the Hill Times
